GlassScriptPhysician profile
Lindsey P Mccracken
NPI 1679894786
$1,906.10
in general payments reported to CMS, 2019-2025
17 companies · $205 in 2025
The $205 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $299 · 2022: $320 · 2023: $461 · 2024: $621 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,287.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $410.57 | 2021-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $383.44 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $329.65 | 2021-2025 | |
| Radius Health, INC. | $124.47 | 2023-2025 | Tymlos |
| Sumitomo Pharma America, INC. | $98.73 | 2023-2025 | Gemtesa |
| Lilly USA, LLC | $90.49 | 2021-2024 | Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $89.07 | 2023-2024 | |
| Inspire Medical Systems, INC. | $85.59 | 2024 | Inspire |
| Exact Sciences Corporation | $60.77 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $57.00 | 2022-2025 | Farxiga, Airsupra |
| Pfizer INC. | $44.68 | 2023-2024 | |
| Esperion Therapeutics, INC. | $32.34 | 2024-2025 | Nexletol |
| Sunovion Pharmaceuticals INC. | $30.15 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $22.90 | 2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $17.78 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.75 | 2021 | |
| Lundbeck LLC | $12.72 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Mccracken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.